Your browser doesn't support javascript.
Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?
Habtemariam, Solomon; Nabavi, Seyed Fazel; Banach, Maciej; Berindan-Neagoe, Ioana; Sarkar, Kasturi; Sil, Parames C; Nabavi, Seyed Mohammad.
  • Habtemariam S; Pharmacognosy Research Laboratories and Herbal Analysis Services, University of Greenwich, Central Avenue, Chatham-Maritime, UK.
  • Nabavi SF; Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran; Division of Translational Medicine, Baqiyatallah Hospital, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Banach M; Department of Hypertension, Medical University of Lodz, Poland; Polish Mothers Memorial Hospital Research Institute, Lodz, Poland.
  • Berindan-Neagoe I; Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Functional Genomics and Experimental Pathology, The Oncology Institute "Prof. Dr. Ion Chiricuta", Cluj-Napoca, Romania; MEDFUTURE-
  • Sarkar K; Department of Microbiology, St. Xavier's College, Kolkata, India.
  • Sil PC; Department of Molecular Medicine, Bose Institute, Kolkata, India.
  • Nabavi SM; Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran; Division of Translational Medicine, Baqiyatallah Hospital, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: nabavi208@gmail.com.
Arch Med Res ; 51(7): 733-735, 2020 10.
Article in English | MEDLINE | ID: covidwho-1023461
ABSTRACT
The discovery of new drugs for treating the new coronavirus (SARS-CoV-2) or repurposing those already in use for other viral infections is possible through understanding of the viral replication cycle and pathogenicity. This article highlights the advantage of targeting one of the non-structural proteins, helicase (nsp13), over other SARS-CoV-2 proteins. Highlighting the experience gained from targeting Nsp13 in similar coronaviruses (SARS-CoV and MERS) and known inhibitors, the article calls for research on helicase inhibitors as potential COVID-19 therapy.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / RNA Helicases / Enzyme Inhibitors / SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Arch Med Res Journal subject: Medicine Year: 2020 Document Type: Article Affiliation country: J.arcmed.2020.05.024

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / RNA Helicases / Enzyme Inhibitors / SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Arch Med Res Journal subject: Medicine Year: 2020 Document Type: Article Affiliation country: J.arcmed.2020.05.024